Annual Meeting, held on 6-9 December, results from the global, multicentre, open-label, randomised, Phase III EPCORE FL-1 ...

Speaking at CDMI Europe 2025, GlobalData pharma analyst George El-Helou says the use of AI in R&D could help mitigate patent ...

GlobalData predicts that Lilly’s retatrutide could reach sales of $15.6bn in 2031. Image credit: Jennie Book / Shutterstock.com. Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight ...

Dyne Therapeutics reported six-month and 24-month data from the Phase I/II trial. Image credit: Sheldon Cooper / SOPA Images / LightRocket via Getty Images. Dyne Therapeutics is seeking US accelerated ...

The safety profile of atogepant over the 24-week period aligned with earlier studies of its use in migraine prevention, with no new safety signals observed. Credit: Komsan Loonprom / Shutterstock.com.

ARCH Ventures-backed Paradigm Health has acquired Roche-owned Flatiron Health’s clinical research business, while closing an oversubscribed $78m Series B financing round to incorporate clinical trials ...

BMS has now said that data from ADEPT-2 will be available in 2026. Image credit: HJBC / Shutterstock.com. Bristol Myers Squibb (BMS) has delayed the data readout from the Phase III ADEPT-2 trial of ...

Capricor’s stock shot up by 371% after it announced the HOPE-3 data. Image credit: Lightspring / Shutterstock.com. Capricor Therapeutics’ stock has soared by more than 370% after a pivotal trial of ...

Kelun-Biotech’s Sac-TMT has met its primary endpoint of PFS improvements in combination with MSD’s Keytruda in comparison to the checkpoint inhibitor alone in a Phase III trial. Image credit: Butusova ...

Novo Nordisk’s amylin agonist, amycretin, has met its key efficacy endpoints in a Phase II study in type 2 diabetes, meaning the Danish pharma will now take the drug to Phase III in the indication.

Belite Bio’s ophthalmology asset, tinlarebant, could become the first US-approved treatment for STDG1, following the positive results of the Phase III DRAGON study. Image credit: Edgar Martirosyan via ...

The two main players within this field are Novo Nordisk and Eli Lilly. Credit: zimmytws via Shutterstock. GLP-1 development has massively increased over the five years since 2020 and has become a ...